Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”

類似資料

• Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients
  著者:: Lee, Sang Jin, 等
  出版事項: (2015)
• Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis
  著者:: CHOI, In Ah, 等
  出版事項: (2018)
• Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
  著者:: Baek, Han Joo, 等
  出版事項: (2019)
• Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study
  著者:: Choi, In Ah, 等
  出版事項: (2020)
• Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study
  著者:: Ha, You-Jung, 等
  出版事項: (2018)